Coherus BioSciences PE Ratio 2013-2021 | CHRS

Current and historical p/e ratio for Coherus BioSciences (CHRS) from 2013 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Coherus BioSciences PE ratio as of September 23, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Coherus BioSciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-09-23 17.52 0.00
2021-06-30 13.83 $-2.32 0.00
2021-03-31 14.61 $-1.22 0.00
2020-12-31 17.38 $1.63 10.66
2020-09-30 18.34 $2.04 8.99
2020-06-30 17.86 $2.34 7.63
2020-03-31 16.22 $1.96 8.28
2019-12-31 18.01 $1.19 15.13
2019-09-30 20.26 $-0.26 0.00
2019-06-30 22.10 $-1.76 0.00
2019-03-31 13.64 $-2.76 0.00
2018-12-31 9.05 $-3.21 0.00
2018-09-30 16.50 $-3.13 0.00
2018-06-30 14.00 $-3.35 0.00
2018-03-31 11.05 $-3.75 0.00
2017-12-31 8.80 $-4.55 0.00
2017-09-30 13.35 $-5.42 0.00
2017-06-30 14.35 $-2.66 0.00
2017-03-31 21.15 $-3.30 0.00
2016-12-31 28.15 $-3.43 0.00
2016-09-30 26.78 $-3.07 0.00
2016-06-30 16.89 $-6.60 0.00
2016-03-31 21.23 $-6.44 0.00
2015-12-31 22.96 $-5.99 0.00
2015-09-30 20.04 $-6.11 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.305B $0.476B
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71